EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: ETRM
- CUSIP: 29365M20
- Previous Close: $6.64
- 50 Day Moving Average: $8.63
- 200 Day Moving Average: $2.29
- 52-Week Range: $1.75 - $88.55
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.05
- P/E Growth: 0.00
- Market Cap: $10.34M
- Outstanding Shares: 1,616,000
- Beta: 2.21
- Net Margins: -3,236.52%
- Return on Equity: -1,361.34%
- Return on Assets: -190.05%
Companies Related to EnteroMedics:
- Debt-to-Equity Ratio: 1.07%
- Current Ratio: 1.20%
- Quick Ratio: 0.93%
What is EnteroMedics' stock symbol?
EnteroMedics trades on the NASDAQ under the ticker symbol "ETRM."
When did EnteroMedics' stock split? How did EnteroMedics' stock split work?
Shares of EnteroMedics reverse split on Friday, January 8th 2016. The 1-15 reverse split was announced on Wednesday, December 23rd 2015. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 7th 2016. An investor that had 100 shares of EnteroMedics stock prior to the reverse split would have 7 shares after the split.
Where is EnteroMedics' stock going? Where will EnteroMedics' stock price be in 2017?
1 analysts have issued 12-month price targets for EnteroMedics' stock. Their predictions range from $3.00 to $11.06. On average, they expect EnteroMedics' stock price to reach $7.03 in the next twelve months.
When will EnteroMedics announce their earnings?
EnteroMedics is scheduled to release their next quarterly earnings announcement on Friday, February, 17th 2017.
Who owns EnteroMedics stock?
EnteroMedics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (10.07%) and CVI Investments, Inc (0.30%). Company insiders that own EnteroMedics stock include Mark B Knudson and Peter M Delange.
Who sold EnteroMedics stock? Who is selling EnteroMedics stock?
EnteroMedics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy EnteroMedics stock?
Shares of EnteroMedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of EnteroMedics stock cost?
One share of EnteroMedics stock can currently be purchased for approximately $6.40.